Diabetes

A recent study found that there was a significant relationship between self-efficacy for disease control and the level of glycemic control.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, talks about the best ways pharmacists can stay updated on advancements in diabetes medications and treatments.

Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, also discusses ways community pharmacists can collaborate with other healthcare professionals to enhance diabetes management.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how pharmacists can help with diabetes prevention and early detection in the community.

A study found that a continuous glucose monitor workflow led by a pharmacist led to reduced HbA1c levels.

A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses a recent meta-analysis that evaluated the efficacy, safety, and clinical implications of insulin icodec.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how insulin icodec differs from existing daily basal insulins and key things pharmacists need to know about the medication.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.

Investigators conducted a study to assess the impact of combined diet and exercise interventions in patients with type 2 diabetes.

Results of the SOUL clinical trial will be presented at a scientific meeting in 2025.

Pharmacist-led medication therapy management can help reduce costs associated with diabetes management.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Without financial incentives, some senators expressed concerns that pharmaceutical research and development would stall.

Senators sought to uncover why prices of Novo Nordisk’s GLP-1 receptor agonist semaglutide are significantly higher in the US compared with countries in Europe.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).

Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).

Catch up on important diabetes news from the month of August.

The device was previously cleared for use in children and adults with type 1 diabetes.